The present invention relates to structural formula I of (R) - N - (5 - ((4- ethyl-piperazin-1-yl) methyl) pyridin-2-yl) -5-fluoro-4- (6 -Fluoro-1-methyl-1,2,3,4-tetrahydrobenzo [4,5] imidazo [1,2-a] pyridin-8-yl) pyrimidin-2-amine (Compound I) The salt form or its crystalline form, the present invention also relates to a method for preparing the salt form and / or its crystalline form of Compound I, a pharmaceutical composition containing the aforementioned salt form and / or crystalline form, and the like The application of the medicine in the pathology or the treatment method for the treatment of diseases, disorders or conditions.本發明係關於結構式I所示之(R)-N-(5-((4-乙基哌嗪-1-基)甲基)吡啶-2-基)-5-氟-4-(6-氟-1-甲基-1,2,3,4-四氫苯並[4,5]咪唑並[1,2-a]吡啶-8-基)嘧啶-2-胺(化合物I)之鹽型或其晶型，本發明亦關於化合物I的鹽型及/或其晶型之製備方法，含有前述鹽型及/或晶型之藥物組合物，以及其等在製備治療疾病、病症或病狀之藥物中之應用或用於治療疾病、病症或病狀之治療方法。
